title: Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
abstract: BACKGROUND
  To define the role of mammalian target of rapamycin inhibitors in kidney transplantation, we compared efficacy and safety of two immunosuppressive regimens-a calcineurin inhibitor-free regimen with depletive induction versus a calcineurin inhibitor-based regimen.
  
  
  METHODS
  De novo renal allograft recipients were randomized before transplantation to receive sirolimus (SRL; n=71, group A) or tacrolimus (n=70, group B). All patients received mycophenolate mofetil and corticosteroids. In group A, patients received rabbit antithymocyte globulin induction. In group B, antithymocyte globulin therapy could be given in case of delayed graft function. The estimated glomerular filtration rate (GFR) (Nankivell's formula) at month 12 was the primary endpoint.
  
  
  RESULTS
  GFR showed no significant difference at month 12, with 56.1 in group A versus 58.4 mL/min/1.73 m in group B. In functioning grafts, renal function was significantly better in the SRL group, with higher GFR values at months 1, 2, 3, 6, and 9 (P<0.05). At month 12, patient survival and incidence of biopsy-proven rejection were not different between groups (95.8% vs. 97.1%, and 16.9% vs. 12.9%, respectively). However, proportion of graft loss was higher with SRL at months 6 and 12 (11.3% vs. 0.0%, P=0.004; 14.1% vs. 4.3%, P=0.044, respectively). Adverse events and premature withdrawals were more frequent with SRL (P<0.001 and P<0.05, respectively), whereas cytomegalovirus infections were more frequent with tacrolimus (P<0.001).
  
  
  CONCLUSIONS
  Patients treated with induction plus SRL, mycophenolate mofetil, and corticosteroids may obtain good renal function but have a higher risk of adverse events, drug withdrawal, and graft loss.
authors.affiliation: Department of Nephrology, Saint-Louis Hospital, Paris, France. denis.glotz@sls.ap-hop-paris.fr
authors.forename: Denis
authors.initials: D
authors.lastname: Glotz
authors.forename: Bernard
authors.initials: B
authors.lastname: Charpentier
authors.forename: Daniel
authors.initials: D
authors.lastname: Abramovicz
authors.forename: Philippe
authors.initials: P
authors.lastname: Lang
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
authors.forename: Gerard
authors.initials: G
authors.lastname: Rifle
authors.forename: Yves
authors.initials: Y
authors.lastname: Vanrenterghem
authors.forename: Francois
authors.initials: F
authors.lastname: Berthoux
authors.forename: Bernard
authors.initials: B
authors.lastname: Bourbigot
authors.forename: Michel
authors.initials: M
authors.lastname: Delahousse
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Chalopin
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Cassuto
authors.forename: Nicole
authors.initials: N
authors.lastname: Lefrançois
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D000961:Antilymphocyte Serum / Q000737:chemistry; D019703:Calcineurin / Q000737:chemistry; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D013256:Steroids; C512542:thymoglobulin; D019703:Calcineurin; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus